Complement C5 Inhibitors (Zilbrysq) — Prior Authorization Guideline
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization guideline for coverage of the complement C5 inhibitor Zilbrysq for adults with anti‑AChR antibody–positive generalized myasthenia gravis (gMG); applies to providers requesting pharmacy benefit approval from CareOregon.
No material clinical or coverage changes in this revision.
Coverage Criteria for Zilbrysq (complement C5 inhibitor)
Initial Therapy
Covered when ALL of the following are met:
Required prior therapy trials (must have trial and failure of ALL):
- Pyridostigmine
- Corticosteroids
- At least two immune‑modulating agents (examples: azathioprine, mycophenolate, cyclosporine, tacrolimus)
- IVIG
- A FcRn antagonist (such as Rystiggo or Vyvgart)
- Uplizna
Reauthorization
Covered when ALL of the following are met:
Ongoing management by a neurologist and documentation of continued clinical benefit should be included in submitted records
Requested therapy must NOT be administered in combination with a FcRn antagonist (for example, Rystiggo or Vyvgart).
Coding and Approval Length
| affected codes | placeholder for codes affected by prior authorization (document lists none explicitly) |
Provider Responsibilities and Documentation Requirements
Prior authorization required for Zilbrysq
Prior authorization is required for Zilbrysq. Initial authorization must be prescribed by or in consultation with a neurologist, for a diagnosis of generalized myasthenia gravis (gMG) clinical classification II–IV, with antibody confirmation and baseline MG‑ADL; approval is for 6 months.
- Prescribed by or in consultation with a neurologist
- Diagnosis of gMG with clinical classification II–IV
- Medical records confirming anti‑AChR antibody positivity
- Baseline MG‑ADL score obtained
- Approval length: 6 months
Step‑therapy: required prior therapy trials and failures
Prior to approval, the member must have trialed and failed all listed therapies.
- Pyridostigmine
- Corticosteroids
- At least two immune‑modulating agents (examples: azathioprine, mycophenolate, cyclosporine, tacrolimus)
- IVIG
- A FcRn antagonist (such as Rystiggo or Vyvgart)
- Uplizna
Required documentation to support PA and reauthorization
Submit supporting clinical records with the prior authorization request.
- Medical records or chart notes confirming anti‑AChR antibody positive diagnosis
- Baseline MG‑ADL score obtained prior to initiation
- For reauthorization: medical records/chart notes demonstrating a clinically significant and meaningful response to therapy
Denial risk: missing antibody or prior‑therapy documentation
Requests may be denied if antibody status or required prior therapy trials are not documented.
- Lack of documentation confirming anti‑acetylcholine receptor (anti‑AChR) antibody positivity
- Failure to document trial and failure of all required prior therapies
Background
This guideline addresses prior authorization for the complement C5 inhibitor Zilbrysq for treatment of adults with generalized myasthenia gravis (gMG). It requires specialist involvement (prescribed by or in consultation with a neurologist), laboratory confirmation of anti‑acetylcholine receptor (anti‑AChR) antibody positivity, documentation of baseline functional status with an MG‑ADL score, and fulfillment of required prior therapy trials before coverage is approved.
Initial approvals are granted only when all criteria are met, including trial and failure of specified therapies (pyridostigmine; corticosteroids; at least two immunomodulators such as azathioprine, mycophenolate, cyclosporine, or tacrolimus; IVIG; a FcRn antagonist such as Rystiggo or Vyvgart; and Uplizna), and are issued for 6 months. Reauthorization requires submission of medical records demonstrating a clinically significant and meaningful response to therapy.
Key Definitions and Clinical Measures
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.